News

Antibody Discovery Strategic Business Report 2025 | Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving ...
ascopubs.org3d
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non ...
FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full ...